HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: gut.2005.076372v1 55/7/946    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guagnini, F Articles by Croci, T Search for Related Content PubMed PubMed Citation Articles by Guagnini, F Articles by Croci, T

Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P

¹ Sanofi-Midy Research Centre, Sanofi-Aventis SpA, Milan, Italy
² Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy
³ Department of Surgery Ospedale San Raffaele, Milan, Italy

Correspondence to:
Correspondence to:
Dr T Croci
Sanofi-Midy Research Centre, Sanofi-Aventis, Via GB Piranesi 38, 20137 Milan, Italy; tiziano.croci{at}sanofi-aventis.com

ABSTRACT
Background and aims: Diverticulosis is a common disease of not completely defined pathogenesis. Motor abnormalities of the intestinal wall have been frequently described but very little is known about their mechanisms. We investigated in vitro the neural response of colonic longitudinal muscle strips from patients undergoing surgery for complicated diverticular disease (diverticulitis).

Methods: The neural contractile response to electrical field stimulation of longitudinal muscle strips from the colon of patients undergoing surgery for colonic cancer or diverticulitis was challenged by different receptor agonists and antagonists.

Results: Contractions of colonic strips from healthy controls and diverticulitis specimens were abolished by atropine. The ß adrenergic agonist (–) isoprenaline and the tachykinin NK₁ receptor antagonist SR140333 had similar potency in reducing the electrical twitch response in controls and diseased tissues, while the cannabinoid receptor agonist (+)WIN 55,212-2 was 100 times more potent in inhibiting contractions in controls (IC50 42 nmol/l) than in diverticulitis strips. SR141716, a selective antagonist of the cannabinoid CB₁ receptor, had no intrinsic activity in control preparations but potentiated the neural twitch in diseased tissues by up to 196% in a concentration dependent manner. SR141716 inhibited (+)WIN 55,212-2 induced relaxation in control strips but had no efficacy on (+)WIN 55,212-2 responses in strips from diverticular disease patients. Colonic levels of the endogenous ligand of cannabinoid and vanilloid TRPV1 receptors anandamide were more than twice those of control tissues (54 v 27 pmol/g tissue). The axonal conduction blocker tetrodotoxin had opposite effects in the two preparations, completely inhibiting the contractions of control strips but potentiating those in diverticular preparations, an effect selectively inhibited by SR140333.

Conclusions: Neural control of colon motility is profoundly altered in patients with diverticulitis. Their raised levels of anandamide, apparent desensitisation of the presynaptic neural cannabinoid CB₁ receptor, and the SR141716 induced intrinsic response, suggest that endocannabinoids may be involved in the pathophysiology of complications of colonic diverticular disease.

Abbreviations: AEA, anandamide or arachidonoyl-ethanolamide; 2-AG, 2-arachidonyl-glycerol; CB₁, cannabinoid receptor subtype 1; EFS, electrical field stimulation; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NK₁, tachykinin receptor subtype 1; RT-PCR, reverse transcription-polymerase chain reaction; TTX, tetrodotoxin; VR1 (also known as TRPV1), vanilloid receptor subtype 1

Keywords: colon diverticulitis; colonic motility; cannabinoids; substance P; tetrodotoxin

This article has been cited by other articles:

				A A Izzo and M Camilleri Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects Gut, August 1, 2008; 57(8): 1140 - 1155. [Abstract] [Full Text] [PDF]

				E. Burcher, F. Shang, F. J. Warner, Q. Du, D. Z. Lubowski, D. W. King, and L. Liu Tachykinin NK2 Receptor and Functional Mechanisms in Human Colon: Changes with Indomethacin and in Diverticular Disease and Ulcerative Colitis J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 170 - 178. [Abstract] [Full Text] [PDF]

				V Di Marzo and A A Izzo Endocannabinoid overactivity and intestinal inflammation. Gut, October 1, 2006; 55(10): 1373 - 1376. [Abstract] [Full Text] [PDF]

				P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]